Literature DB >> 21493216

Primary TEP placement in patients with laryngopharyngeal free tissue reconstruction and salivary bypass tube placement.

Vasu Divi1, Derrick T Lin, Kevin Emerick, James Rocco, Daniel G Deschler.   

Abstract

The authors examined the feasibility and advantages of primary tracheoesophageal puncture (TEP) with intraoperative placement of the voice prosthesis for patients undergoing laryngopharyngectomy requiring free tissue reconstruction and salivary bypass tube placement. Six patients were identified; 4 underwent total laryngopharyngectomy, and 2 underwent total laryngectomy with partial pharyngectomy. All 6 required free tissue reconstruction, and a salivary bypass tube was placed in all cases. All patients had a 20F Indwelling Blom-Singer prosthesis (InHealth Technologies, Carpinteria, California) placed. No complications were noted with intraoperative prosthesis placement. No prostheses were dislodged in the postoperative period. At 6 months, 4 patients available for evaluation had successful voice outcomes, and 3 were disease free. This study demonstrates the effectiveness of voice prosthesis placement at the time of primary TEP associated with free tissue reconstruction of a laryngopharyngeal defect with salivary bypass tube placement.

Entities:  

Mesh:

Year:  2011        PMID: 21493216     DOI: 10.1177/0194599810391960

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  2 in total

1.  Primary tracheoesophageal puncture with supraclavicular artery island flap after total laryngectomy or laryngopharyngectomy.

Authors:  Rosh K V Sethi; Elliott D Kozin; Allen C Lam; Kevin S Emerick; Daniel G Deschler
Journal:  Otolaryngol Head Neck Surg       Date:  2014-06-12       Impact factor: 3.497

2.  Office-based tracheoesophageal puncture: updates in techniques and outcomes.

Authors:  Jennifer L Bergeron; Nausheen Jamal; Andrew Erman; Dinesh K Chhetri
Journal:  Am J Otolaryngol       Date:  2014-04-27       Impact factor: 1.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.